What are analysts saying about the CSL share price?

The CSL Limited (ASX: CSL) share price has been on form over the last 12 months.

As you can see on the chart below, the biotherapeutics company’s shares have risen over 14% to $300.24.

As a comparison, the ASX 200 index is down almost 3% over the same period.

Has the CSL share price peaked?

If the broker community is to be believed, the CSL share price could still have plenty of gas in its tank and be destined to keep climbing from here.

For example, analysts at Citi, Macquarie, and Morgans, to name just three, all have the equivalent of buy ratings on its shares with price targets implying double digit returns.

Citi currently has a buy rating and $350.00 price target. Based on the latest CSL share price, this implies potential upside of approximately 16.5% over the next 12 months.

Macquarie is almost as bullish with its outperform rating and $344.00 price target, which implies almost 15% upside for investors.

Finally, Morgans has an add rating and $337.92 price target, which suggests that the CSL share price can rise approximately 12.5% from here.

What are brokers saying?

All three brokers are positive on the company’s outlook and expect strong earnings growth in the coming years.

This is being underpinned by a significant improvement in plasma collection conditions, the acquisition of Vifor Pharma, new product launches, and strong demand for immunoglobulins.

Morgans commented:

We believe CSL is poised to break-out this year, a COVID exit trade, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses.

Citi recently boosted its earnings forecasts for similar reasons. It explained:

We increase our FY23-25e NPATA per share (Core EPS) by +1%/+7%/+10% reflecting the faster than expected recovery in plasma collections and higher sales. Our TP moves to $350 (from $335) Maintain Buy.

All in all, it may not be too late to snap up this high-quality company.

The post What are analysts saying about the CSL share price? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Invested $6,000 in CSL shares 5 years ago? Here’s how much dividend income you’ve earned
• Morgans says these are among the best blue chip ASX 200 shares you can buy
• If I’d invested $1,000 in CSL shares 24 years ago, here’s how much I’d have now!
• Why did the CSL share price lag the ASX 200 in the first quarter of 2023?
• Build your portfolio around these ASX 200 blue chip shares: brokers

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/4kEhZ0G